Novavax COVID-19 vaccine 89% effective in UK trial, less in South Africa
The study took place as the more highly transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation.
Britain's Prime Minister Boris Johnson poses for a photograph with a vial of the AstraZeneca/Oxford University COVID-19 candidate vaccine, known as AZD1222, at Wockhardt's pharmaceutical manufacturing facility in Wrexham, Wales, Britain November 30, 2020.(photo credit: PAUL ELLIS/ REUTERS)ByREUTERS
